Attached files
| file | filename |
|---|---|
| EX-10.1 - EXHIBIT 10.1 - Arbutus Biopharma Corp | exhibit101q22016.htm |
| EX-32.2 - EXHIBIT 32.2 - Arbutus Biopharma Corp | exhibit322q22016.htm |
| EX-31.2 - EXHIBIT 31.2 - Arbutus Biopharma Corp | exhibit312q22016.htm |
| EX-31.1 - EXHIBIT 31.1 - Arbutus Biopharma Corp | exhibit311q22016.htm |
| EX-10.3 - EXHIBIT 10.3 - Arbutus Biopharma Corp | exhibit103q22016.htm |
| EX-10.2 - EXHIBIT 10.2 - Arbutus Biopharma Corp | exhibit102q22016.htm |
| 10-Q - ARBUTUS Q2 2016 10-Q - Arbutus Biopharma Corp | arbutusq22016.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (the “Company”) for the quarter ended June 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Mark Murray, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company. |
Date: August 4, 2016
/s/ Mark Murray | |
Name: Mark Murray | |
Title: President and Chief Executive Officer | |